Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) EBIT Margin (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed EBIT Margin for 4 consecutive years, with 515.95% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 46980.0% to 515.95% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1130.65% through Dec 2025, down 3309.0% year-over-year, with the annual reading at 1130.65% for FY2025, 3309.0% down from the prior year.
  • EBIT Margin hit 515.95% in Q4 2025 for Taysha Gene Therapies, up from 1347.08% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 620637.5% in Q1 2022 to a low of 1915.38% in Q2 2024.
  • Historically, EBIT Margin has averaged 41443.21% across 4 years, with a median of 515.95% in 2025.
  • Biggest five-year swings in EBIT Margin: tumbled -62098937bps in 2023 and later skyrocketed 56830bps in 2025.
  • Year by year, EBIT Margin stood at 4135.33% in 2022, then tumbled by -111bps to 450.78% in 2023, then tumbled by -119bps to 985.76% in 2024, then surged by 48bps to 515.95% in 2025.
  • Business Quant data shows EBIT Margin for TSHA at 515.95% in Q4 2025, 1347.08% in Q2 2025, and 930.54% in Q1 2025.